Referral patterns of GIST patients: data from a nationwide study
DOI:
https://doi.org/10.2340/1651-226X.2024.23722Keywords:
Gastrointestinal stromal tumor, GIST, registry, reference center, systemic treatment, mutation analysisAbstract
Background: This study compares the characteristics, referral and treatment patterns and overall survival (OS) of gastrointestinal stromal tumor (GIST) patients treated in reference and non-reference centers in the Netherlands.
Patients and methods: This retrospective cohort study on patients diagnosed between 2016 and 2019, utilises data from the Netherlands Cancer Registry and the Dutch Nationwide Pathology Database. Patients were categorized into two groups: patients diagnosed in or referred to reference centers and patients diagnosed in non-reference centers without referral.
Results: This study included 1,550 GIST patients with a median age of 67.0 in reference and 68.0 years in non-reference centers. Eighty-seven per cent of patients were diagnosed in non-reference centers, of which 36.5% (493/1,352) were referred to a reference center. Referral rates were higher for high-risk (62.2% [74/119]) and metastatic patients (67.2% [90/134]). Mutation analysis was performed in 96.9% and 87.6% of these cases in reference and in non-reference centers (p < 0.01), respectively. Systemic therapy was given in reference centers versus non-reference in 89.5% versus 82.0% (p < 0.01) of high-risk and in 94.1% versus 65.9% (p < 0.01) of metastatic patients, respectively. The proportion of positive resection margins and tumor rupture did not differ between reference and non-reference centers. Median OS was not reached.
Conclusion: A substantial amount of metastatic GIST patients in non-reference centers did not receive systemic treatment. This might be due to valid reasons. However, optimisation of the referral strategy of GIST patients in the Netherlands could benefit patients. Further research is needed to explore reasons for not starting systemic treatment in metastatic GIST patients.
Downloads
References
Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130(10):1466–78. https://doi.org/10.5858/2006-130-1466-GSTROM DOI: https://doi.org/10.5858/2006-130-1466-GSTROM
Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39–46. https://doi.org/10.1016/j.canep.2015.10.031 DOI: https://doi.org/10.1016/j.canep.2015.10.031
Federatie medisch Specialisten. Normeringsrapport van SONCOS 2022. Available from: https://demedischspecialist.nl/normeringsrapportvan-soncos [cited 02-05-2023]
Casali PG, Blay JY, Abecassis N, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagno-sis, treatment and follow-up. Ann Oncol. 2022;33(1):20–33. DOI: https://doi.org/10.1016/j.annonc.2021.09.005
Joensuu H, Vehtari A, Riihimäki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled popula-tion-based cohorts. Lancet Oncol. 2012;13(3):265–74. https://doi.org/10.1016/S1470-2045(11)70299-6 DOI: https://doi.org/10.1016/S1470-2045(11)70299-6
Bauer S, George S, von Mehren M, Heinrich MC. Early and next-generation KIT/PDGFRA kinase inhibitors and the future of treatment for advanced gastrointestinal stromal tumor. Front Oncol. 2021;11:672500. https://doi.org/10.3389/fonc.2021.672500 DOI: https://doi.org/10.3389/fonc.2021.672500
Steeghs EMP, Gelderblom H, Ho VKY, et al. Nationwide evaluation of mutation-tailored treatment of gastrointestinal stromal tumors in daily clinical practice. Gastric Cancer. 2021;24(5):990–1002. DOI: https://doi.org/10.1007/s10120-021-01190-9
Verschoor AJ, Bovée J, Overbeek LIH, Hogendoorn PCW, Gelderblom H. The incidence, mutational status, risk classification and referral pattern of gastro-intestinal stromal tumours in the Netherlands: a nationwide pathology registry (PALGA) study. Virchows Arch. 2018;472(2):221–9. https://doi.org/10.1007/s00428-017-2285-x DOI: https://doi.org/10.1007/s00428-017-2285-x
Casparie M, Tiebosch AT, Burger G, et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the na-tionwide histopathology and cytopathology data network and archive. Cell Oncol. 2007;29(1):19–24. https://doi.org/10.1155/2007/971816 DOI: https://doi.org/10.1155/2007/971816
Blay JY, Soibinet P, Penel N, et al. Improved survival using specialized multidisciplinary board in sarcoma patients. Ann Oncol. 2017;28(11):2852–9. https://doi.org/10.1093/annonc/mdx484 DOI: https://doi.org/10.1093/annonc/mdx484
Blay JY, Honoré C, Stoeckle E, et al. Surgery in reference centers improves survival of sarcoma patients: a nationwide study. Ann Oncol. 2019;30(7):1143–53. https://doi.org/10.1093/annonc/mdz124 DOI: https://doi.org/10.1093/annonc/mdz124
Gronchi A, Bonvalot S, Poveda Velasco A, et al. Quality of surgery and outcome in localized gastrointestinal stromal tumors treated with-in an international intergroup randomized clinical trial of adjuvant imatinib. JAMA Surg. 2020;155(6):e200397. https://doi.org/10.1001/jamasurg.2020.0397 DOI: https://doi.org/10.1001/jamasurg.2020.0397
Hølmebakk T, Bjerkehagen B, Hompland I, Stoldt S, Boye K. Relationship between R1 resection, tumour rupture and recurrence in resect-ed gastrointestinal stromal tumour. Br J Surg. 2019;106(4):419–26. https://doi.org/10.1002/bjs.11027 DOI: https://doi.org/10.1002/bjs.11027
Blum MG, Bilimoria KY, Wayne JD, de Hoyos AL, Talamonti MS, Adley B. Surgical considerations for the management and resection of esophageal gastrointestinal stromal tumors. AnnThorac Surg. 2007;84(5):1717–23. https://doi.org/10.1016/j.athoracsur.2007.05.071 DOI: https://doi.org/10.1016/j.athoracsur.2007.05.071
Kameyama H, Kanda T, Tajima Y, et al. Management of rectal gastrointestinal stromal tumor. Transl Gastroenterol Hepatol. 2018;3:8. https://doi.org/10.21037/tgh.2018.01.08 DOI: https://doi.org/10.21037/tgh.2018.01.08
Ijzerman NS, Mohammadi M, Tzanis D, et al. Quality of treatment and surgical approach for rectal gastrointestinal stromal tumour (GIST) in a large European cohort. Eur J Surg Oncol. 2020;46(6):1124–30. https://doi.org/10.1016/j.ejso.2020.02.033 DOI: https://doi.org/10.1016/j.ejso.2020.02.033
Joensuu H, Wardelmann E, Sihto H, et al. Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib: an exploratory analysis of a randomized clinical trial. JAMA Oncol. 2017;3(5):602–9. https://doi.org/10.1001/jamaoncol.2016.5751 DOI: https://doi.org/10.1001/jamaoncol.2016.5751
Florindez J, Trent J. Low frequency of mutation testing in the United States: an analysis of 3866 GIST patients. Am J Clin Oncol. 2020;43(4):270–8. https://doi.org/10.1097/COC.0000000000000659 DOI: https://doi.org/10.1097/COC.0000000000000659
Bartholomew AJ, Dohnalek H, Prins PA, et al. Underuse of exon mutational analysis for gastrointestinal stromal tumors. J Surg Res. 2018;231:43–8. https://doi.org/10.1016/j.jss.2018.05.014 DOI: https://doi.org/10.1016/j.jss.2018.05.014
Farag S, van Coevorden F, Sneekes E, et al. Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespec-tive of performance score or comorbidity – a retrospective multicentre study in a large cohort of GIST patients. Eur J Cancer. 2017;86:318–25. https://doi.org/10.1016/j.ejca.2017.09.017 DOI: https://doi.org/10.1016/j.ejca.2017.09.017
Nishida T, Sakai Y, Takagi M, et al. Adherence to the guidelines and the pathological diagnosis of high-risk gastrointestinal stromal tu-mors in the real world. Gastric Cancer. 2020;23(1):118–25. https://doi.org/10.1007/s10120-019-00966-4 DOI: https://doi.org/10.1007/s10120-019-00966-4
Bischof DA, Dodson R, Jimenez MC, et al. Adherence to guidelines for adjuvant imatinib therapy for GIST: a multi-institutional analysis. J Gastrointest Surg. 2015;19(6):1022–8. https://doi.org/10.1007/s11605-015-2782-7 DOI: https://doi.org/10.1007/s11605-015-2782-7
Pisters PWT, Blanke CD, von Mehren M, et al. A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices. Ann Oncol. 2011;22(11):2523–9. https://doi.org/10.1093/annonc/mdq773 DOI: https://doi.org/10.1093/annonc/mdq773
Bilimoria KY, Wayne JD, Merkow RP, et al. Incorporation of adjuvant therapy into the multimodality management of gastrointestinal stromal tumors of the stomach in the United States. Ann Surg Oncol. 2012;19(1):184–91. https://doi.org/10.1245/s10434-011-1842-9 DOI: https://doi.org/10.1245/s10434-011-1842-9
Bischof DA, Kim Y, Blazer DG, 3rdet al. Surgical management of advanced gastrointestinal stromal tumors: an international multi-institutional analysis of 158 patients. J Am Coll Surg. 2014;219(3):439–49. https://doi.org/10.1016/j.jamcollsurg.2014.02.037 DOI: https://doi.org/10.1016/j.jamcollsurg.2014.02.037
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Evelyne Roets, Nikki S. Ijzerman, Vincent K.Y. Ho, Ingrid M.E. Desar, Anna K.L. Reyners, Hans Gelderblom, Dirk J. Grünhagen, Boudewijn van Etten, Winan J. van Houdt, Winette T.A. van der Graaf, Neeltje Steeghs
This work is licensed under a Creative Commons Attribution 4.0 International License.
